TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
Vancouver, British Columbia--(Newsfile Co
2025-12-17 5:00 PM EST
TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive
2025-12-15 5:00 PM EST
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company expands its...
2025-12-10 5:00 PM EST
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health maintenance...
2025-12-08 5:00 PM EST
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands. This collaboration...
2025-12-05 5:00 PM EST
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), an innovator in smart temperature-controlled medical devices, is pleased to announce t
2025-12-02 5:00 PM EST
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") announce that it has signed a definitive exclusive commercial distribution agreement with Guri A.A.O. ("Guri
2025-11-26 4:51 PM EST
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 3 months, commencing on November 18, 2025. This news release...
2025-11-18 7:00 AM EST
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon initiative, Beyond Type Run. Through this partnership, TempraMed joins Beyond Type 1 in empowering 55 inspiring runners-including many who are living with...
2025-10-27 7:00 AM EDT
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purchase warrant of the Company (each, a "Warrant"). Each...
2025-10-21 7:00 AM EDT
TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025. Further, the board of directors (the "Board") of the Company announced today that it has received and accepted...
2025-10-15 7:00 AM EDT
TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - TempraMed Technologies Ltd. (the "Company") is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the "Prospectus"), with the British Columbia Securities Commission and is now a reporting issuer in the Province of British Columbia, effective as of September 29, 2025. The Prospectus was filed for, among other things, the...
2025-10-10 7:00 AM EDT
TempraMed Closes Oversubscribed C$7.4M Financing and Advances Toward Go Public Listing
Sammamish, Washington--(Newsfile Corp. - September 3, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator redefining how temperature-sensitive medications are stored, managed and protected, is pleased to announce significant corporate and capital markets milestones, including the successful close of an oversubscribed C$7.4 million private placement financing and strong progress toward its public listing on the Canadian Securities Exchange (CSE), expected...
2025-09-03 7:00 AM EDT
TempraMed Partners with the Diabetes Education & Camping Association of the USA (DECA), Supporting Safe Insulin Storage for Children at Diabetes Camps Across the United States
Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive storage devices to support...
2025-08-07 7:00 AM EDT